BCL2 and B-cell chronic lymphocytic leukemia: In this regard, several trials have demonstrated remarkable success of the FD treatment approach in treatment-naïve CLL, particularly combinations of the BCL-2 inhibitor venetoclax alongside ibrutinib (ibrutinib-venetoclax) (12, 13) or the anti-CD20 inhibitor obinutuzumab (obinutuzumab-venetoclax) (14–16).